However, the available data concerning these impacts remain limited and occasionally contradictory.<h4>Material and methods</h4>We conducted a retrospective analysis of cancer patients who received PD-1/PD-L1 inhibitor therapy at the same institution from November 2022 to May 2023. This evidence concerns the gene CD274 and cancer.